CIDP Clinical Trial

Posted on

Open-Label Phase 2 study with SAR445088, a Complement C1s inhibitor, in adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by Sanofi

This global multicenter study will evaluate the efficacy, safety and tolerability of SAR445088 in CIDP. SAR445088 (previously known as BIVV020) is an investigational monoclonal antibody that targets Complement C1s and has a subcutaneous route with self-administration. The study is seeking patients with CIDP belonging to three groups: (1) patients who are successfully treated with standard of care therapies, immunoglobulin or corticosteroids, (2) patients who have failed or inadequate response to these therapies, or (3) patients who are naïve to these therapies, i.e. never received treatment.

The study consists of three parts: an initial 24-week treatment period (Part A), followed by an optional extension period providing up to 52 additional weeks of treatment (Part B), and a further optional treatment period (Part C) where participants will continue receiving SAR445088.

For more information on this study, please visit: